

1 **Lab-on-a-chip multiplexed electrochemical sensor enables simultaneous** 2 **detection of SARS-CoV-2 RNA and host antibodies**

3 Devora Najjar^{1, 2, 4#}, Joshua Rainbow^{1, 3#}, Sanjay Sharma Timilsina^{1#}, Pawan Jolly^{1#}, Helena de Puig^{1, 2#},
4 Mohamed Yafia¹, Nolan Durr¹, Hani Sallum¹, Galit Alter⁵, Jonathan Z. Li⁶, Xu G. Yu^{5, 6}, David R. Walt^{1,}
5 ^{7, 8}, Joseph A. Paradiso⁴, Pedro Estrela³, James J. Collins^{1, 2, 9*} and Donald E. Ingber^{1, 7, 10, 11*}

6
7

8 ¹Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA

9 ²Institute for Medical Engineering and Science, Department of Biological Engineering, Massachusetts
10 Institute of Technology, Cambridge, MA 02139, USA

11 ³Centre for Biosensors, Bioelectronics and Biodevices (C3Bio) and Department of Electronic and
12 Electrical Engineering, University of Bath, Bath BA2 7AY, UK

13 ⁴MIT Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

14 ⁵Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

15 ⁶Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA

16 ⁷Harvard Medical School, Boston, MA 02115, USA

17 ⁸Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA

18 ⁹Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA
19 02142, USA

20 ¹⁰Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, MA 02115,
21 USA

22 ¹¹Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston,
23 MA 02115, USA

24

25 *Co-corresponding authors. Email: don.ingber@wyss.harvard.edu (D.E.I.), jimjc@mit.edu (J.J.C.)

26

27 # These authors contributed equally

28

29 **Keywords:** Lab-on-a-chip, multiplexed, CRISPR, serology, antibody, electrochemical sensor, COVID-
30 19, saliva, SARS-CoV-2, point-of-care.

31

32 **Abstract**

33
34 **The current COVID-19 pandemic highlights the continued need for rapid, accurate, and cost-**
35 **effective point-of-care (POC) diagnostics that can accurately assess an individual's infection and**
36 **immunity status for SARS-CoV-2. As the virus continues to spread and vaccines become more**
37 **widely available, detecting viral RNA and serological biomarkers can provide critical insights into**
38 **the status of infectious, previously infectious, and vaccinated individuals over time. Here, we**
39 **describe an integrated, low-cost, 3D printed, lab-on-a-chip device that extracts, concentrates, and**
40 **amplifies viral RNA from unprocessed patient saliva and simultaneously detects RNA and multiple**
41 **host anti-SARS-CoV-2 antibodies via multiplexed electrochemical (EC) outputs in two hours. The**
42 **EC sensor platform enables single-molecule CRISPR/Cas-based molecular detection of SARS-CoV-**
43 **2 viral RNA as well as serological detection of antibodies against the three immunodominant SARS-**
44 **CoV-2 viral antigens. This study demonstrates that microfluidic EC sensors can enable multiplexed**
45 **POC diagnostics that perform on par with traditional laboratory-based techniques, enabling**
46 **cheaper and more widespread monitoring of infection and immunity over time.**

47
48 The COVID-19 pandemic has highlighted the need for cost-effective diagnostics for SARS-CoV-2 RNA
49 as well as for detection of antibodies generated by the host in response to infection. This type of
50 multifunctional detection platform will be particularly useful for diagnosis of both acute and convalescent
51 infections, as well as for assessing patient immunization status following vaccination. The clinical
52 timeline of SARS-CoV-2 infection consists of an acute phase, when viral RNA is detectable in clinical
53 samples, such as saliva or nasopharyngeal swabs, followed by a convalescent phase when serology
54 biomarkers, such as IgG antibodies, are present in saliva and serum¹. Therefore, simultaneous analysis of
55 these different biomarkers in clinical samples as the disease progresses could provide more accurate
56 results for disease monitoring and management.

57

58 Molecular (nucleic acid) diagnostics that detect the presence of viral RNA are key to detecting the virus
59 during the first 5 days of infection, with a viral load peak around day 4 (**Supplementary Fig. S1**)²⁻⁴.
60 Following the first few days of infection, the host produces IgM, IgA, and IgG antibodies in a process
61 known as seroconversion. These antibodies often become stable after the first 6 days of seroconversion
62 and their titers can remain stable over months^{5,6}. The presence of different antibody types varies during
63 infection⁷ and correlates with disease severity^{8,9}. In particular, extensive cohort studies in hospitalized
64 patients show that IgG antibodies against different viral proteins (e.g., nucleocapsid or spike proteins)
65 correlate with disease severity and outcomes. For example, antibodies against the spike (S) protein are
66 more specific¹⁰ and correlate with virus neutralization⁸, while antibodies against the nucleocapsid (N)
67 protein have longer clearance rates¹¹ and might appear earlier during infection¹². Therefore, serological
68 assays that detect the host's antibodies developed after an infection can widen the testing window for
69 SARS-CoV-2 beyond the molecular diagnostic timeframe and provide insights into the patient's
70 progression. Such assays also may be used to determine whether titers are maintained over time and thus
71 the effectiveness of vaccination responses. For example, SARS-CoV-2 vaccine efficacy trials have
72 highlighted a direct correlation between the titer of antibodies targeting the Receptor Binding Domain
73 (RBD) found in the S1 subunit of the S protein, the neutralizing antibody titer, and vaccine efficacy¹³.
74 Thus, the development of serological assays targeted to individual SARS-CoV-2 viral antigens could
75 have important implications for predicting the efficacy of vaccines and estimating the need for boosters.
76
77 Molecular diagnostics, on the other hand, commonly involve methods such as quantitative Polymerase
78 Chain Reaction (qPCR), which require rigorous sample preparation and temperature control, cold storage
79 of reagents, expensive instrumentation (requiring routine maintenance), and trained personnel to run the
80 tests. While there are home diagnostic tests approved for use by the U.S. Food and Drug Administration
81 (FDA), many of these tests either involve self-collection and mailing to a central laboratory or are based
82 on rapid antigen tests, which have shown to be less accurate than nucleic acid tests, such as qPCR¹⁴.
83 During the last few years, powerful diagnostic techniques that capitalize on CRISPR (Clustered Regularly

84 Interspaced Short Palindromic Repeats) technology and associated programmable endonucleases have
85 gained significant interest, due in part to their high specificity, programmability, and capacity to work at
86 physiological conditions¹⁵⁻¹⁹. CRISPR-based diagnostics capitalize on endonucleases, such as Cas12a,
87 which has a specific cleavage activity towards double-stranded DNA (dsDNA) fragments matching its
88 guide RNA (gRNA) sequence. Once the Cas12a-gRNA complex binds to its dsDNA target, it activates
89 and subsequently engages in indiscriminate collateral hydrolysis of nearby single-stranded DNA
90 (ssDNA)^{20,21}.

91
92 Electrochemical (EC) methods of CRISPR-based nucleic acid detection typically combine nucleic acid
93 probes conjugated on an electrode with CRISPR Cas effectors and have detection limits in the picomolar-
94 femtomolar (10^{-12} - 10^{-15}) range²²⁻²⁶. Unfortunately, those detection limits are inadequate for diagnosing
95 SARS-CoV-2 in clinical samples, which require ultrasensitive RNA detection at the attomolar (10^{-18})
96 scale. To overcome this limitation, amplification techniques such as loop-mediated isothermal
97 amplification (LAMP) can be performed prior to Cas12a detection, which improves the sensitivity of
98 fluorescent CRISPR-based assays by orders of magnitude^{15-17,19,27}.

99
100 The combination of serological and nucleic acid diagnostics can improve the overall accuracy of SARS-
101 CoV-2 diagnosis²⁸ and provide qualitative data on the patient's disease severity and state of progression.
102 However, workflows for SARS-CoV-2 diagnosis that integrate serological and nucleic acid tests are
103 currently limited as these assays require laboratory equipment such as pipettes, centrifuges, and heating
104 blocks, as well as specialized technical skills. Despite the advances to make SARS-CoV-2 tests as widely
105 available as possible, a lab-on-a-chip (LOC) platform for point-of-care (POC) use that can detect both
106 SARS-CoV-2 RNA and serological markers is not yet available.

107
108 EC biosensors offer a particularly promising solution to achieve ultra-sensitive, selective, multiplexed,
109 quantitative, and cost-effective LOC detection of both nucleic acids and proteins; they also offer the

110 potential to interface with electronic medical records, integrated cloud systems, and telemedicine. Despite
111 their potential, EC diagnostic platforms have only been used to detect either nucleic acid or proteins
112 individually^{26,29} and have been limited to platforms that require multiple liquid handling steps and
113 specialized equipment. Here, we describe a low-cost, 3D printed, self-contained, LOC diagnostic platform
114 that is capable of concurrent detection of both SARS-CoV-2 nucleic acids and host antibodies directed
115 against the virus from unprocessed saliva samples. This device integrates microfluidics that enable
116 automated liquid handling for sample preparation and a simple and sensitive read-out for both viral RNA
117 as well as host antibodies. The simplicity of this device makes it user-friendly and should enable its use
118 for POC testing within hospitals and in COVID-19 testing clinics.

119

120 **Results**

121 **Design of the microfluidic electrochemical lab-on-a-chip platform**

122 In considering the design of an LOC diagnostic device, we focused on accuracy, ease of use, and a
123 capacity to integrate with digital health platforms. Towards this goal, we fabricated a microfluidic chip
124 capable of processing untreated saliva to detect both viral RNA and host antibodies on the same EC
125 sensor chip (**Fig. 1**). We chose saliva over the more common nasopharyngeal swab specimens on our
126 device due to saliva's ease of self-collection and increased clinical sensitivity due to a high viral load^{30,31}.
127 Because unprocessed saliva is viscous and contains nucleases that could inhibit a downstream reaction,
128 viral RNA is typically purified from saliva using costly and complicated nucleic acid purification kits.
129 However, to eliminate the need for purification prior to reaction, we experimented with various sample
130 preparation workflows that would allow for viral lysis and nuclease inactivation (**Supplementary Fig.**
131 **S2**). Among different buffers tested, we found that incubating the saliva sample with a Proteinase K³²
132 solution at 55°C followed by a 95°C inactivation effectively lysed the sample and eliminated false positive
133 signals without inhibiting the performance of the downstream LAMP and CRISPR-based detection steps.
134 Following the sample preparation step, we needed a method to capture the nucleic acids from the saliva

135 sample. We found that a polyethersulfone (PES) membrane was able to concentrate the RNA without
136 inhibiting the downstream reactions³³⁻³⁶.

137

138 Overall, the device incorporates a 500 μ L sample preparation chamber which is used for the saliva-based
139 RNA detection, a 50 μ L reaction chamber that contains the PES membrane, a 25 μ L LAMP reservoir, a
140 22 μ L CRISPR reservoir, and a 20 μ L reservoir for direct saliva-based antibody detection. The compact
141 design allowed for the use of two high-power resistors as heating elements (**Fig. 1b**), one beneath the
142 sample preparation reservoir and the other beneath the reaction chamber. The LAMP and CRISPR
143 reservoirs were isolated from the sample preparation reservoir and reaction chamber to assure that there
144 was no carryover heating from the heated elements during the sample preparation and concentration.

145

146 To optimize chip functionality, we tested a variety of reservoir and channel dimensions and placements to
147 ensure uniform heating and precise fluid flow (**Supplementary Fig. S3**). The chip was designed with
148 different channel dimensions to establish resistors to the fluid flow while the fluids were controlled by a
149 small, fingertip-sized DC peristaltic pump with a maximum flow rate of 200 μ l/min controlled by an
150 Arduino microcontroller. The channels leading to the reservoirs were designed with higher resistance to
151 avoid any backflow or cross-contamination with the reservoirs (400 x 150 μ m) (**Supplementary Fig. S4**),
152 while the ends of the channels leading to the reservoirs were designed with a stepped stop valve to stop
153 any flow from the reaction chamber to the reservoirs. We tested a variety of reaction chamber geometries
154 to ensure that the PES membrane surface area was adequate for nucleic acid capture and that the chamber
155 had optimal fluid retention over the course of the reaction, settling on a serpentine shape (**Supplementary**
156 **Fig. S3**) and designed higher resistance on the flow path to the EC sensor chip to avoid unwanted flow
157 before the desired time point.

158

159 The workflow of the sample-to-answer microfluidic detection device with fluid flow driven by an
160 Arduino-controlled small peristaltic pump is as follows. First, the user manually inputs saliva onto the

161 antibody detection reservoir (**Fig. 1a**, 5) and the RNA sample preparation reservoir (**Fig. 1a**, 1). In the
162 RNA sample preparation chamber, the saliva combines with a Proteinase K solution and is heated to 55°C
163 for 15 mins followed by 95°C for 5 mins using integrated high-power resistors to allow for virus lysis and
164 nuclease inactivation³². The saliva sample is then pumped over the PES membrane within the reaction
165 chamber, where the RNA binds to the membrane. The reaction chamber is heated to 95°C for an
166 additional 3-5 min to ensure denaturation of potential reaction inhibitors. The LAMP solution is then
167 pumped from the reservoir into the reaction chamber and incubated at 65°C for 30 min, followed by the
168 CRISPR mixture and incubated at 37°C for an additional 30 min, after which it is pumped over the EC
169 sensor chip to incubate. Saliva for antibody detection is then directly pumped over the EC sensor chip and
170 incubated. The chip is washed with phosphate buffered saline with Tween® 20 (PBST) followed by the
171 addition of Polystreptavidin-Horseradish Peroxidase (HRP) and a precipitating form of
172 tetramethylbenzidine (TMB), after which the chip is read using a potentiostat. A more in-depth visual of
173 the microfluidic chip and its workflow is provided in **Supplementary Fig. S5**.

174

175 **Integrated CRISPR-based molecular diagnostic assay**

176 The CRISPR-Cas RNA detection experiments reported here capitalize on Cas12a from *Lachnospiraceae*
177 bacterium ND2006, which has specific cleavage activity towards dsDNA fragments matching its guide
178 RNA (gRNA) sequence. Upon target binding, activated Cas12a-gRNA engages in collateral cleavage of
179 nearby single-stranded DNA (ssDNA)^{20,21} that can be read optically as an increase in fluorescence due to
180 the hydrolysis of a fluorophore-quencher labeled ssDNA reporter. As a result, the signal obtained from
181 the fluorescent assay will be high in the presence of its SARS-CoV-2 target and low when it is not
182 detected. LAMP primers³⁷⁻⁴¹ and Cas12a-gRNAs were evaluated from a range of conserved regions in the
183 SARS-CoV-2 genome to determine the most sensitive combinations using commercially available,
184 synthetic full-length SARS-CoV-2 genomic RNA. The ORF1a assay, which targets a highly conserved
185 region in the SARS-CoV-2 viral genome, had a limit of detection (LOD) of 2.3 viral RNA copies/μL with
186 a reaction time of 50 min (**Supplementary Table S1, Fig. S6-7**). This LOD is comparable to high-

187 performance SARS-CoV-2 reverse transcription quantitative polymerase chain reaction (RT-qPCR)
188 assays⁴² with half the time to result. To confirm that the assay was able to detect SARS-CoV-2 active
189 virus, the ORF1a assay primers and guide RNA were further validated using 11 SARS-CoV-2 RT-qPCR
190 negative patient saliva samples and 19 SARS-CoV-2 RT-qPCR positive saliva samples with a range of
191 cycle threshold (C_T) values (**Supplementary Fig. S8-S9, Supplementary Table S2**).

192
193 To integrate the CRISPR-based molecular assay onto the EC sensor platform, we designed a biotinylated
194 ssDNA reporter probe (RP) that partially hybridized to peptide nucleic acid (PNA) capture probes
195 immobilized on the surface of the antifouling composite-coated gold electrodes⁴³(**Fig. 2a**). Functionalized
196 EC biosensors were incubated with samples containing the LAMP/Cas12a mix which includes the
197 biotinylated ssDNA RP. In the presence of SARS-CoV-2 target RNA, Cas12a collaterally cleaved the
198 biotinylated ssDNA reporter, leading to a reduction of binding of poly-HRP-streptavidin and thus, a
199 reduction in the precipitation of TMB deposited locally on the surface of the electrode⁴³. Reduced
200 precipitation of TMB was recorded as peak current, which was measured using cyclic voltammetry (CV)
201 by sweeping the voltage between -0.5 and 0.5 V (**Fig. 2b**). As a result, the signal obtained from the EC
202 platform demonstrated an inversely proportional relationship with target concentrations. It should be
203 noted that the LAMP amplification prior to the CRISPR-based sample detection increases the sensitivity
204 of the sensor, allowing for a consistently distinguishable signal from samples that are at or above the limit
205 of detection (LOD) of the sensor (**Fig. 2c**).

206
207 To optimize the binding efficiency of the PNA-based CRISPR-EC sensor platform, we varied the
208 concentration and incubation time of the RP to obtain a rapid, high signal-to-noise ratio (**Supplementary**
209 **Fig. S10-11**). Among all the concentrations tested, 1nM RP and 5-min incubation produced a high signal
210 with no background. Interestingly, the CRISPR-EC sensor platform gave a single molecule LOD of 0.8
211 cp/ μ L, which was nearly four times more sensitive than the initial fluorescence-based assays used to
212 validate the primer and guide pairs (**Supplementary Table S1, Figs. S7 and S12**). To determine the

213 potential clinical value of the optimized CRISPR-EC sensor platform, we extracted RNA from 19 patient
214 saliva samples that were positive for SARS-CoV-2 based on RT-qPCR with a range of CT values and 11
215 RT-qPCR negative clinical saliva samples (**Supplementary Fig. S8**). The current measured in the form
216 of the output signal from the electrodes was clearly distinguishable (p-value <0.0001) when comparing
217 the SARS-CoV-2 positive and negative samples (**Fig. 2c**). In addition, ROC curve analysis demonstrated
218 an impressive correlation with RT-qPCR and CRISPR-based fluorescent detection, with 100% accuracy,
219 and AUC=1 (**Fig. 2d**).

220

221 **Multiplexed serology EC assay**

222 Multiplexed assays that diagnose disease by combining viral RNA with serology markers can lead to a
223 more robust understanding of the progression of diseases, including SARS-CoV-2⁴⁴. The primary
224 antigens that elicit antibodies during coronavirus infection are the N and S proteins¹⁰. The N protein is the
225 most abundant viral protein and is highly conserved among the coronavirus family⁴⁵, with several studies
226 indicating that IgG antibodies targeting the N protein may be more sensitive due to their early appearance
227 and longer clearance rates during and post-infection^{7,11,12}. While the S protein is less conserved than the N
228 protein, it is highly immunogenic due to the S1 subunit (S1) which mediates attachment to target cells⁴⁶.
229 Studies indicate IgG antibodies against S1 are more specific and strongly correlate with virus
230 neutralization^{47,48}. Antibodies targeting S1 and the ribosomal binding domain within this subunit (S1-
231 RBD) may also be used to assess the effectiveness of vaccination responses and titer maintenance over
232 time, with SARS-CoV-2 vaccine efficacy trials highlighting a direct correlation between the titer of
233 antibodies targeting the RBD of the S protein, the neutralizing antibody titer, and vaccine efficacy¹³.
234 Therefore, to maximize our assay's accuracy, we leveraged the multiplexing capabilities of our EC sensor
235 and fabricated a multiplexed serology assay capable of measuring antibodies against the S1, S1-RBD, and
236 N proteins for detection of a patient's immunity, whether through prior viral infection or vaccination.

237

238 We began by using an Enzyme-Linked Immunosorbent Assay (ELISA) to optimize the reagents prior to
239 assembling the multiplexed serology EC sensor chip (**Supplementary Figs. S13-S17**). Initially, a small
240 set of high-titer and low-titer positive clinical plasma samples were used to optimize the assay over a
241 broad range of IgG titers. The best performing capture antigens were S1, S1-RBD, and N, and the best
242 performing detection antibodies were biotinylated goat anti-human IgG, rabbit anti-human IgM, and goat
243 anti-human IgA. We validated the ELISA accuracy with 58 SARS-CoV-2 plasma samples from patients
244 with a prior positive SARS-CoV-2 RT-qPCR result and 54 SARS-CoV-2 negative samples. Out of the 54
245 negative SARS-CoV-2 samples, 22 were collected before the onset of the SARS-CoV-2 pandemic. The
246 ROC curve analysis of the ELISA results yielded areas under the curve (AUC) between 0.68 and 0.89 for
247 IgG, IgM and IgA (**Supplementary Figs. S15-S17**).

248
249 Next, we used the optimized reagents to develop a multiplexed EC sensor to measure the humoral
250 response against SARS-CoV-2 from patient plasma samples. We fabricated an EC sensor with an
251 antifouling coating composed of bovine serum albumin and reduced graphene crosslinked with
252 glutaraldehyde (BSA/rGO_x/GA)²⁵⁻²⁷, where each electrode was individually functionalized with S1
253 (electrode 1), S1-RBD (electrode 2), N (electrode 3), or BSA as an on-chip negative control (electrode 4)
254 to perform a multi-antigen sandwich EC ELISA (**Fig. 3a**). We used an affinity-based sandwich strategy
255 for the EC sensor assay, meaning that when SARS-CoV-2 antibodies were present, they bound to both the
256 surface antigen and secondary antibody, leading to an increase in the EC signal. Each immunoglobulin
257 isotype (IgG, IgM, IgA) was detected individually on the multiplexed EC sensor chips. **Fig. 3b-e** shows
258 typical CV results obtained with the multiplexed EC sensor chips for detection of anti-SARS-CoV-2 IgG
259 using SARS-CoV-2 positive and negative clinical samples.

260
261 We optimized the assay conditions of the serology EC assays to obtain the highest signal-to-noise ratios
262 on both high- and low-titer clinical samples by varying factors such as plasma dilutions, sample
263 incubation times, and TMB precipitation times (**Supplementary Figs. S18-S20**). We found that a 30-min

264 sample incubation at a 1:9 plasma dilution with a 3-min TMB precipitation time resulted in the highest
265 sensitivity and specificity for detection of SARS-CoV-2 antibodies in clinical plasma samples
266 (**Supplementary Fig. S19c**).

267
268 We then evaluated the accuracy of the EC serology platform using plasma samples from patients with a
269 prior SARS-CoV-2 RT-qPCR positive result. We performed an ROC curve analysis utilizing the 58
270 SARS-CoV-2 positive plasma samples and 54 SARS-CoV-2 negative samples used to optimize the
271 ELISA assay (**Fig. 3f, Supplementary S21a**). The clinical samples had a wide range of IgG levels that
272 were shown to have excellent correlation with our assay (**Supplementary Fig. S22**). Overall, the AUC
273 for anti-SARS-CoV-2 IgG (**Fig. 3g**) was higher than IgM (**Supplementary S21b**), whereas IgA's AUC
274 was lowest (between 0.57 and 0.78) and did not add diagnostic value (**Supplementary Fig. S21b**). The
275 specificity of each individual sensor modified with either S1, N or RBD was over 95% for IgG. Further
276 analysis of the multiplexed assay's ROC curves showed S1-RBD was the most accurate capture probe
277 (AUC=1 for IgG), followed by N and S1 (**Fig. 3g, Supplement Fig. S21a**).

278
279 In addition, we found that combining the results of the three antigens as a multiplexed readout resulted in
280 a slight increase in accuracy when assessing a patient's immune status (AUC=1 for IgG) (**Fig. 3f-g,**
281 **combined**). The combined EC IgG assay had an excellent correlation with prior SARS-CoV-2 infection
282 and was shown to be 100% accurate (100% sensitivity and specificity); we therefore used this for
283 subsequent experiments on the multiplexed EC sensor chips. We also found the EC sensor-based serology
284 platform to be more accurate in detecting samples from patients with prior SARS-CoV-2 infection than
285 the ELISA. The high specificity of the EC sensor platform may be attributed to the low non-specific
286 binding on our nanocomposite-coated EC electrodes²⁵⁻²⁷.

287

288 **A multiplexed viral RNA and antibody diagnostic in a 3D-printed LOC platform**

289 We next worked to combine both EC sensors to create a multiplexed assay for simultaneous viral RNA
290 and serological biomarker detection on-chip to facilitate increased sensitivity and specificity of SARS-
291 CoV-2 detection⁴⁴. Saliva is an excellent source of both viral RNA as well as host antibodies (IgG, IgM,
292 IgA) in SARS-CoV-2 patients⁴⁹, and hence is an ideal sample for a multiplexed assay for viral RNA and
293 serology. Unfortunately, the patient saliva samples used for this study had to be heat-inactivated before
294 use as saliva from SARS-CoV-2 infected patients are of a highly contagious nature. Because high heat
295 denatures the antibodies,¹ we spiked a National Institute for Biological Standards and Control (NIBSC)
296 SARS-CoV-2 IgG calibrant into heat-inactivated saliva samples at 1:20 dilution to simulate the ratio of
297 IgG present in saliva. After confirming that the signal outputs from the spiked saliva samples were
298 consistent with the signals generated from the plasma samples (**Supplementary Fig. S23**), we modified
299 the EC sensor chip so that the four electrodes could be used individually to detect the three antigens (S1,
300 N, S1-RBD) and PNA (**Fig. 4a**).

301
302 To study the performance of our multiplexed EC sensor, we first conducted a two-step assay where
303 antibody-spiked saliva was split into two volumes: 15 μ l was incubated on the chip for multiplexed
304 serological detection of the host's anti-SARS-CoV-2 antibodies and 280 μ l was used for RNA extraction
305 followed by the LAMP-CRISPR-based assay and incubation on the same chip. Following incubation of
306 both samples on the electrodes, we simultaneously measured the SARS-CoV-2 viral RNA and host
307 antibodies on-chip with the EC sensor readout of precipitating TMB following the addition of poly-HRP
308 streptavidin. We validated the assay performance by testing the four possible combinations of serology
309 and RNA-positive and RNA-negative clinical samples (**Supplementary Fig S24**). We achieved a very
310 high probability (student's t-test $p < 0.0001$) in distinguishing positive from negative samples with an
311 ultra-low background signal in all the combinations tested. Taken together, these results showed excellent
312 multiplexing capacity for SARS-CoV-2 viral RNA and host antibodies on the chips with 100%
313 correlation in specificity and sensitivity.

314

315 Following these validation experiments, we integrated the multiplexed EC sensor chip into the compact
316 LOC microfluidic platform (**Fig. 1**) to test the capabilities for automated viral RNA preparation prior to
317 the EC sensor readout. Using the same functionalized chip assay as described above, each
318 clinical saliva sample was split between the RNA and antibody reservoirs and the assay was performed as
319 described in **Fig. 1a** and **Supplementary Fig. S5**. Similar to the initial validation of the multiplexed
320 assay, the assay performance of the LOC microfluidic system with integrated EC sensor chip was
321 validated by testing the four possible combinations of serology and RNA-positive and RNA-negative
322 clinical samples (**Fig. 4b-e**). Clinical IgG negative samples showed no EC signal for the N, S1 and S1-
323 RBD antigen-conjugated electrodes (**Fig. 4b, c**), whereas clinical samples from patients exposed to
324 SARS-CoV-2 showed high IgG loads in all three antigen test areas (student's t-test for S1 and S1-RBD
325 $p < 0.0001$ and for N $p = 0.0004$) (**Fig. 4 d, e**). Moreover, we measured high signals on the PNA conjugated
326 electrode for all clinical samples that were negative for SARS-CoV-2 viral RNA (**Fig. 4b, d**) and low or
327 no currents on the PNA electrode for SARS-CoV-2 RT-qPCR RNA positive samples (student's t-test
328 $p = 0.0002$) (**Fig. 4 c, e**). Taken together, the results show that the LOC system can effectively prepare and
329 deliver unprocessed saliva samples containing both SARS-CoV-2 viral RNA and host antibodies for on-
330 chip simultaneous multiplexed detection with 100% correlation in specificity and sensitivity. A cost
331 analysis of the LOC multiplexed diagnostic can be seen in **Supplementary Table S4**.

332

333 Discussion

334 Molecular diagnostics for detection of pathogen RNA and serological assays for assessment of host
335 antibody responses are complementary tools that provide critical information to respond to disease
336 outbreaks, assess vaccination status, and manage patient care and risks. While molecular diagnostics for
337 SARS-CoV-2 RNA can be important indicators of viral shedding during the infectious phase of the
338 disease, sensitivity can vary considerably over the course of the infection. Depending on factors such as
339 sample types, virus variants, and infection severity⁵⁰⁻⁵⁵, diagnostics can sometimes detect the presence of
340 viral RNA long after an infectious phase has subsided,⁵⁶ which can complicate patient management and

341 severely impact society and the economy. Serological assays can provide insights following viral
342 infection, with antibodies prevalent in a patient's saliva and serum months after infection¹. Therefore,
343 combining molecular diagnostics with serological assays can improve accurate monitoring both during
344 and following an infection.

345
346 Multiplexed serology assays combined with nucleic acid assays are increasingly relevant due to the
347 present level of infection and the current rate of vaccine rollout, which can be used to assess a patient's
348 response to vaccination¹³. For example, currently available SARS-CoV-2 vaccines induce antibody
349 production against SARS-CoV-2 S and S1-RBD proteins, and vaccinated individuals who have not been
350 infected with SARS-CoV-2 are expected to develop measurable antibodies against the S, but not the N
351 protein⁵⁷. Therefore, multiplexed serology assays that target antibodies against several viral antigens can
352 become key for seroprevalence studies to estimate the proportion of people in a population that have been
353 infected, including asymptomatic infection, and/or immunized with vaccines. This information is key to
354 estimate herd immunity and vaccine efficacy¹³, which is critical for the decision to reopen economies^{58,59}.

355
356 In the present study, we described an innovative sample-to-answer diagnostic POC platform that
357 integrates ultrasensitive and highly specific multiplexed EC sensors within an LOC microfluidic platform,
358 which can rapidly detect both SARS-CoV-2 viral RNA and antibodies from clinical saliva samples. Due
359 to its customizable surface chemistry, these EC sensors enable the detection of different targets such as
360 nucleic acids and proteins. The simple and inexpensive BSA/rGOx/GA-based surface chemistry of the
361 antifouling sensor coating combined with a poly-HRP streptavidin/TMB output allows for high
362 conductivity and low nonspecific binding, leading to ultra-low EC background and improved
363 sensitivity^{37,60}.

364
365 We validated the EC sensor platform for serology and obtained an accuracy of 100% (100% sensitivity
366 and 100% specificity) for IgG as compared to traditional ELISA, with S1-RBD showing the highest

367 accuracy in detecting IgG in clinical samples. S1-RBD having the highest accuracy may be explained by
368 the RBD domain being a highly immunogenic epitope for development of neutralizing antibodies during
369 the humoral response to SARS-CoV-2⁴⁷. We then characterized a multiplexed EC sensor that detects
370 antibodies against relevant viral structural proteins (S1-RBD, S1, and N) for a variety of antibody
371 isotypes (IgG, IgM, and IgA), allowing for a more robust understanding of the humoral response in
372 patients. Importantly, we also found that simultaneous multiplexed detection of different viral antigens
373 led to increased diagnostic sensitivity.

374
375 We further demonstrated the versatility of our EC sensor platform by performing nucleic acid detection
376 through a customized molecular assay that builds off of CRISPR-based diagnostics which combines
377 isothermal nucleic acid amplification with CRISPR-Cas enzymes, such as DETECTR¹⁵ or
378 SHERLOCK^{16,17}, to target SARS-CoV-2 viral RNA in saliva. While other CRISPR-Cas diagnostics for
379 SARS-CoV-2 have been described⁶¹⁻⁶³, they are typically limited to fluorescence and lateral flow
380 readouts. In this study, we showed that EC CRISPR diagnostics can detect even more sensitively than
381 fluorescence-based CRISPR assays using EC sensors, with a similar time to result.

382
383 Finally, we designed and tested a novel microfluidic LOC platform that integrates with the multiplexed
384 EC sensor for simultaneous detection of both RNA and IgG in clinical saliva samples. Saliva is an
385 excellent alternative to nasopharyngeal swabs and nasal swabs for SARS-CoV-2 diagnosis, as it is simple
386 to collect, does not require extensive collection equipment, and has been shown to provide both nucleic
387 acid and serological data during and post infection or vaccination^{1,30,64}. We tested the sensor on four
388 categories of SARS-CoV-2 clinical saliva samples: RNA negative and antibody negative, RNA positive
389 and antibody positive, RNA negative and antibody positive, and RNA positive and antibody negative.
390 Clear differentiation was seen between IgG negative and positive samples for N, S1 and S1-RBD antigen-
391 conjugated electrodes (student's t-test for S1 and S1-RBD $p < 0.0001$ and for N $p = 0.0004$) as well as

392 between SARS-CoV-2 viral RNA (student's t-test $p=0.0002$) within two hours after inputting the
393 unprocessed saliva sample, highlighting the utility of our platform.

394
395 Our LOC microfluidic device, with its low cost and compact design, limits user steps to avoid possible
396 sources of contamination or human-introduced error to allow for device use by untrained end-users and
397 further increasing its potential as a POC testing system. A key difference between our work and that of
398 other recently published POC CRISPR-based electrochemical detection platforms²²⁻²⁴ is our use of HRP-
399 TMB for readout, which enables further amplification of the EC signal for both the serological and
400 CRISPR-based RNA sensors. Importantly, our platform also integrates microfluidics to enable automated
401 sample preparation, temperature control, and reagent addition steps, thereby creating an easy-to-use
402 sample-to-answer platform that is more appropriate for POC applications. Novel graphene FET-based EC
403 biosensors for SARS-CoV-2 have displayed similar levels of sensitivity to the 0.8 ct/ μ l LOD shown
404 here⁶⁷, but this earlier assay was only validated for VTM-based nasopharyngeal swab samples and more
405 significantly, it does not have multiplexing capabilities. With our integrated device, we are able to
406 perform both serological and RNA detection from a saliva sample, which does not require specialized
407 collection reagents or equipment, and the results are reported concurrently. To our knowledge, this is the
408 first report of an EC diagnostic device that is multiplexed, highly sensitive, and capable of processing raw
409 biological samples such as saliva.

410
411 Limitations to our study include the small set of clinical COVID-19 saliva samples available due to the
412 difficulty in acquiring saliva through biorepositories that do not routinely collect this sample type.
413 However, the fact that we were able to obtain 100% accuracy with clinical samples that contained a wide
414 range of viral loads strongly suggests that our CRISPR-based EC sensor platform could become a faster,
415 simpler, and cheaper non-invasive strategy compared to RT-qPCR and traditional fluorescent diagnostics.
416 Additionally, we are currently implementing a peristaltic pump for fluid movement and a potentiostat for
417 the readout of the EC sensor chips. While this would not be a limitation to making this multiplexed

418 diagnostic useful for healthcare and clinical POC settings, it would be difficult for at-home POC use in its
419 current form. Further work to integrate the electronics and readouts, as well as sourcing recyclable or
420 biodegradable materials and producing at scale, could allow this device to be affordable and useful into a
421 home setting.

422

423 As the COVID-19 pandemic has shown, there is a critical need to rapidly adapt current testing strategies
424 to more quickly and easily monitor both the infection and immune status of patients. Knowledge of
425 infection stages can help curb disease spread, while insights on antibody titer levels can help with
426 understanding how novel variants may affect individuals with immune protection through infection,
427 vaccination, or a combination of the two. The streamlined workflow and multiplexing capabilities of our
428 EC sensor is a step towards building the infrastructure necessary to provide this information to clinicians
429 and members of the public alike.

430

431 **Methods**

432 **Chip preparation**

433 Gold chips were custom manufactured by Telic Company using a standard photolithography process with
434 deposition of 15 nm of chromium and 100 nm of gold on a glass wafer. The area of electrodes was
435 controlled by depositing a layer of 2 μm of insulating layer (SU-8). Prior to use, gold chips were cleaned
436 by 5-min sonication in acetone (Sigma Aldrich, USA, no. 650501) followed by isopropanol (Sigma
437 Aldrich, USA, no. W292907). To ensure a clean surface, the chips were then treated with oxygen plasma
438 using a Zepto Diener plasma cleaner (Diener Electronics, Germany) at 0.5 mbar and 50% power for 2
439 min.

440

441 **Nanocomposite preparation and activation**

442 Nanocomposite coating was prepared using the previously described method⁴³. Briefly, amine-functional
443 reduced graphene oxide (Sigma Aldrich, USA, no. 805432) was dissolved in 5 mg/mL BSA (Sigma

444 Aldrich, USA, no. 05470) in 10 mM PBS solution, pH 7.4 (Sigma Aldrich, USA, no. D8537), and
445 ultrasonicated for 1 h using 1-s on/off cycles at 50% power. The solution was then denatured by heating
446 at 105 °C for 5 min and centrifuged to remove the excess aggregates. The nanomaterial solution was then
447 crosslinked by mixing with 70% glutaraldehyde (Sigma Aldrich, USA, no. G7776) at a ratio of 69:1,
448 deposited on the glass chip with the gold electrodes and incubated in a humidity chamber for 20-24 h to
449 form a conductive nanocomposite⁶⁵. After nanocomposite deposition, gold chips were washed in PBS by
450 agitation (500 rpm) for 10 min and dried with pressurized air. EDC (Thermo Fisher Scientific, USA, no.
451 22980) and NHS (Sigma Aldrich, USA, no. 130672) were dissolved in 50 mM MES buffer (pH 6.2) at
452 400 mM and 200 mM, respectively, and deposited on nanocomposite-covered gold chips for 30 min.
453 After surface activation, chips were quickly rinsed with ultra-pure water and dried, and the capture probes
454 were spotted on top of the working electrode area.

455

456 **Clinical samples and ethics statement**

457 De-identified clinical saliva samples from the Dominican Republic were obtained from Boca Biolistics
458 under their ethical approvals. RT-qPCR was performed by Boca Biolistics using the Perkin Elmer New
459 Coronavirus Nucleic Acid Detection kit. De-identified clinical plasma samples were obtained from the
460 Crimson Biomaterials Collection Core Facility at Partners Healthcare (currently Mass General Brigham).
461 Additional de-identified clinical plasma and saliva samples were obtained through the Massachusetts
462 Consortium on Pathogen Readiness (MassCPR); these samples had been collected by Prof. Jonathan Li
463 and Prof. Xu Yu. Additional pre-SARS-CoV-2 pandemic samples were obtained from the Walt
464 Laboratory at Brigham and Women's Hospital. The Institutional Review Boards at the MGH, MGB, and
465 Harvard University as well as the Harvard Committee on Microbiological Safety approved the use of the
466 clinical samples in this study. All clinical samples were inactivated by heating at 65 °C for 30 min prior to
467 use to denature SARS-CoV-2 virions that might be present in the samples. We extracted total RNA from
468 saliva via a QIAamp viral RNA mini kit (Qiagen), following manufacturer's instructions and eluted the
469 total RNA in nuclease-free water.

470

471 **CRISPR-based RNA assay with fluorescent reporter**

472 CRISPR-based assays require the selection of both LAMP isothermal amplification primers and gRNAs
473 to detect the LAMP amplicons. LAMP amplification primers (Supplementary Table S3) were selected
474 after testing a range of LAMP primers, including some from the literature³⁷⁻⁴¹. Cas12a gRNAs consist of
475 two parts: the handle region (UAAUUUCUACUAAGUGUAGAU) that the Cas protein recognizes and
476 binds, and a user-defined region at the 3' end of the handle that determines the specificity to the target.
477 Spacer regions were selected following established guidelines²⁰. To synthesize the gRNA (gRNA
478 sequence: UAA UUU CUA CUA AGU GUA GAU GGU GAA ACA UUU GTC ACG CA), synthetic
479 DNA with an upstream T7 promoter sequence (5' GAAATTAATACGACTCACTATAGGG 3') was
480 purchased from Integrated DNA Technologies (IDT) and in vitro transcribed using the HiScribe T7 High
481 Yield RNA Synthesis kit from New England Biolabs (NEB). Reactions were incubated for 16 h at 37 °C,
482 treated with DNase I (NEB), and purified using the RNA Clean & Concentrator-25 kit (ZymoResearch).
483 gRNA was quantified (ng/μL) on a Nanodrop 2000 (Thermo Fisher Scientific).

484

485 Simulated SARS-CoV-2 samples were prepared by serially diluting full-length SARS-CoV-2 viral RNA
486 (Twist Biosciences, MT106054.1) in nuclease-free water. Viral RNA extracted from saliva samples was
487 used after purification via the QiAmp viral RNA extraction kit, as explained above. RNA was then
488 amplified by LAMP and further detected by collateral cleavage of the fluorophore-quenched ssDNA
489 reporter probe. Briefly, 5 μL of the diluted genomic DNA, or clinical sample RNA extract was added to
490 2.5 μL of the 10X primer mix (Supplementary Table S3), 12.5 μL of the LAMP master mix (NEB), and 5
491 μL of water. LAMP mixtures were incubated for 30 min at 65 °C. After LAMP amplification, 4 μL of the
492 amplified LAMP mixture were mixed with 11 μL of nuclease-free water and 5 μL of the CRISPR
493 mixture, which contained 1 μM ssDNA fluorophore-quencher reporter (sequence: 6-
494 FAM/TTATT/IABkFQ), 100 nM Cas, 200 nM gRNA in 10X NEB 2.1 buffer. Reactions were incubated
495 at 37 °C for 20 min and fluorescence kinetics were measured using a BioTek NEO HTS plate reader

496 (BioTek Instruments) with readings every 2 min (excitation: 485 nm; emission 528 nm).

497

498 **Chip functionalization for the CRISPR-based RNA assay with electrochemical reporter**

499 For CRISPR sensors, custom-synthesized amine-terminated peptide nucleic acid (AEEA-

500 ACAACAACAACAACA) where AEEA is an O-linker was obtained from PNAbio, USA. PNA is a

501 synthetic analog of DNA with a backbone utilizing repeating units of N-(2-aminoethyl) glycine linked

502 through amide bonds. PNA contains the same four nucleotide bases as DNA (adenine, cytosine, guanine,

503 and thymine) but are connected through methylene bridges and a carbonyl group to the central amine of a

504 peptide backbone⁶⁶. Stock PNA was diluted to 20 μ M in 50mM MES buffer and spotted on the working

505 electrode. One electrode was spotted with 1 mg/mL BSA as a negative control. The spotted chips were

506 incubated overnight in a humidity chamber. After conjugation, chips were washed and quenched in 1 M

507 ethanolamine dissolved in 10 mM PBS, pH 7.4 for 30 min and blocked with 1% BSA in 10 mM PBS

508 containing 0.05% Tween 20.

509

510 **CRISPR-based RNA assay with electrochemical reporter**

511 The reporter sequence for CRISPR-based EC assays was a ssDNA (sequence: /5Biosg/AT TAT TAT

512 TAT TAT TTG TTG TTG TTG TTG T) conjugated to a biotin that bound to poly-streptavidin-HRP.

513 Upon Cas12a activation, the ssDNA-biotin reporter is cleaved in solution, thus preventing binding to the

514 complementary PNA sequence on the surface. Poly-streptavidin-HRP is then added and able to bind to

515 the ssDNA reporter-biotin. The concentration of HRP bound to the electrode was read by HRP-dependent

516 oxidation of precipitating TMB (TMB enhanced one component, Sigma Aldrich, US, no. T9455). TMB

517 precipitation forms an insulating, non-soluble layer on the electrode surface. Full-length genomic RNA

518 (Twist Biosciences, MT106054.1) was serially diluted and amplified with 2X LAMP master mix (NEB)

519 for 30 min at 65 °C. Viral RNA was extracted from saliva via purification with the QiAmp viral RNA

520 extraction kit. Similar to the protocol explained above, 5 μ L of the viral RNA was added to 2.5 μ L of the

521 10X primer mix (Supplementary Table S3), 12.5 μ L of the LAMP master mix (NEB), and 5 μ L of water.

522 LAMP mixtures were incubated for 30 min at 65 °C. After LAMP amplification, 4 µL of the amplified
523 LAMP product was mixed with 10 µL of nuclease-free water and 5 µL of the CRISPR mix, which
524 contained 4 nM reporter, 100 nM Cas, 200 nM gRNA in 10X NEB 2.1 buffer. Mixtures were incubated
525 for 20 min at 37 °C, during which time the ssDNA biotinylated reporter was cleaved. After that, 15 µL of
526 the LAMP/reporter/Cas mixtures was deposited on the chips for 5 min. Thereafter, the chips were washed
527 and incubated with poly-HRP streptavidin and TMB for 5 min and 1 min, respectively. Final
528 measurement was then performed in PBST using a potentiostat (Autolab PGSTAT128N, Metrohm; VSP,
529 Bio-Logic) by a CV scan with 1 V/s scan rate between -0.5 and 0.5 V vs on-chip integrated gold quasi
530 reference electrode. Peak oxidation current was calculated using Nova 1.11 software. Cyclic voltammetry
531 allowed us to measure attomolar concentrations of SARS-CoV-2 target RNA.

532

533 **Serology ELISA assay**

534 ELISA assays were optimized in a 96-well plate format. 100 µL of 1 µg/mL antigens: Spike S1
535 (SinoBiological, China, no. 40591-V08H), Nucleocapsid (RayBiotech, US, no. 130-10760) and Spike
536 (S1) RBD (The Native Antigen Company, UK, no. REC31849) were prepared in a 10 mM PBS buffer at
537 pH 7.4 and added to Nunc™ MaxiSorp™ ELISA plates (BioLegend, no. 423501) and immobilized on the
538 plates by overnight incubation at 4 °C. The plates were washed three times with 200 µL of PBST
539 followed by the addition of 250 µL of 5% Blotto for 1 h. After washing the plates, 100 µL of the clinical
540 plasma samples diluted in 2.5% Blotto was added and incubated for 1h at RT. Plates were further washed
541 and HRP conjugated anti-human IgA/IgM or biotin-conjugated anti-human IgG detection antibodies were
542 added for 1h. The secondary antibodies used were: HRP conjugated anti-human IgM (Human IgM mu
543 chain rabbit Antibody, Rockland, us, no. 109-4107) or IgA (AffiniPure Goat Anti-Human Serum IgA, α
544 chain specific, Jackson ImmunoResearch, US, no. 109-005-011) or biotin-anti-human IgG (AffiniPure
545 Goat Anti-Rabbit IgG, Fc fragment specific, Jackson ImmunoResearch, US, no. 111-005-008). The IgG
546 plate was further mixed with 100µL of Streptavidin-HRP (1:200 dilution in 2.5 % Blotto) and washed.
547 100 µL of turbo TMB (Thermo Scientific, no. 34022) was added for 20 min followed by the addition of

548 100 μ L of sulfuric acid (0.1M H₂SO₄ in Water) to stop the reaction. The absorbance of the plates was
549 immediately read using a microplate reader (BioTek NEO HTS plate reader, BioTek Instruments) at 450
550 nm.

551

552 **Electrochemical serology assay**

553 To translate the ELISA assays to EC readouts, Spike S1, Nucleocapsid and Spike-RBD were diluted to 1
554 mg/mL in the PBS buffer and spotted in three electrodes of the EC chip. An additional electrode was
555 spotted with 1 mg/mL BSA as a negative control. The spotted chips were incubated overnight in a
556 humidity chamber. After conjugation, chips were washed and quenched in 1 M ethanolamine (Sigma
557 aldrich, US, no.E9508) dissolved in 10 mM PBS, pH 7.4 for 30 min and blocked with 5% Biotin (Santa
558 Cruz Biotechnology, US, no. sc-2324) in 10 mM PBS containing 0.05% Tween 20 (Sigma aldrich, US,
559 no. P9416). The fabricated sensor was then used to detect immunoglobulins from clinical samples. Each
560 sensor was either used to detect IgG, IgM, or IgA against the three antigens that were immobilized on the
561 chips. 1.5 μ L of clinical plasma samples were mixed with 13.5 μ L of 2.5% Biotin and incubated on the
562 chips for 30 min at RT followed by a rinsing step. After that, HRP conjugated anti-human IgM /IgA/
563 biotin-anti-human IgG was added for 30 min at RT. 1 μ g/mL of poly-HRP-streptavidin
564 (ThermoScientific, US, no. N200) diluted in 0.1 % BSA in PBST was added to chips with IgG for 5 min.
565 The chips were rinsed and precipitating TMB was added for 3 min followed by final rinse and EC
566 measurement using a potentiostat by cyclic voltammograms with a scan rate of 1 V/s between -0.5 and
567 0.5 V vs on-chip integrated gold quasi reference electrode. Additional antibodies were screened,
568 including: F(ab')₂ Goat anti-Human IgG-Fc Fragment Antibody Biotinylated (Bethyl Laboratories, no.
569 A80-148B), Goat anti-Human IgG Fc Secondary Antibody, Biotin (ThermoFisher Scientific, US, no.
570 A18821), Purified anti-human IgG Fc Antibody (BioLegend, no. 409302), Purified anti-human IgG Fc
571 Antibody (BioLegend, no. 410701), and AffiniPure F(ab')₂ Fragment Goat Anti-Human IgG, Fc γ
572 fragment specific-biotin (Jackson ImmunoResearch, US, no. 109-006-170).

573

574 **Multiplexed electrochemical serology and CRISPR-based RNA detection**

575 Multiplexed sensors for both nucleic acid and host antibody detection were prepared by spotting three
576 electrodes of the EC chip with proteins: Spike S1, Nucleocapsid and Spike-RBD; and spotting the amine-
577 terminated peptide nucleic acid (AEEA-ACAACAACAACA) reporter on the fourth electrode. The
578 spotted chips were incubated overnight in a humidity chamber. After conjugation, chips were washed and
579 quenched in 1 M ethanolamine (Sigma aldrich, US, no.E9508) dissolved in 10 mM PBS, pH 7.4 for 30
580 min and blocked with 1% BSA in 10 mM PBS containing 0.05% Tween 20 (Sigma Aldrich, US, no.
581 P9416). The fabricated sensor was then used to detect IgG's as well as viral RNA from clinical samples.

582
583 Multiplexed chips were used to detect viral RNA as well as IgG against the three antigens that were
584 immobilized on the EC sensor chips. Negative control saliva (RT-qPCR negative) was heat-inactivated
585 and spiked with plasma at a ratio of 1:20 to simulate IgG concentrations in saliva. Two experiments were
586 done in parallel on each chip, as follows: (1) 15µl of plasma-spiked saliva was used for the serology
587 assays as explained above. Briefly, 0.75 µl of the plasma sample was mixed with 14.25 µl of control
588 saliva and incubated on the chips for 30 min at RT followed by a rinsing step. After that, biotin-anti-
589 human IgG was added for 30 min at RT. Chips were then rinsed. (2) In parallel, RNA extracted from RT-
590 qPCR positive and negative clinical samples was amplified by LAMP for 30min at 65°C as explained
591 above. Then, 4 µL of the amplified LAMP product was mixed the CRISPR mix, which contained the
592 biotinylated reporter and incubated for 20min at 37°C. 15 µL of the LAMP/reporter/Cas mixtures was
593 deposited on the chips after the chips had been exposed to SARS-CoV-2 IgG. Thereafter, the chips were
594 washed and incubated with poly-HRP streptavidin and TMB for 1 min. Final measurement was then
595 performed in PBST using a potentiostat (Autolab PGSTAT128N, Metrohm; VSP, Bio-Logic) by a CV
596 scan with 1 V/s scan rate between -0.5 and 0.5 V vs on-chip integrated gold quasi reference electrode.
597 Peak oxidation current was calculated using Nova 1.11 software. Cyclic voltammetry allowed us to
598 measure both the presence of IgG antibodies as well as attomolar concentrations of SARS-CoV-2 target
599 RNA.

600

601 **Microfluidic chip for multiplexed electrochemical serology and CRISPR-based RNA detection**

602 A microfluidic chip for a point-of-care diagnostic that integrated the multiplexed chip was designed using
603 Autocad software and printed on a Formlabs Form 3B 3D SLA printer in grey resin, Version 4 (Formlabs
604 RS-F2-GPGR-04). The layer thickness chosen for the 3D printing parameters is 50 μm . The chip is
605 cleaned in an isopropanol bath for 20 min, then cured in a heated UV chamber for 1 h at 60°C (Form
606 wash and Form cure, Formlabs). The chip was designed with chambers for saliva, LAMP reagents, and
607 CRISPR reagents, as well as a reaction chamber lined with a PES membrane and a waste port. The PES
608 membrane (Millipore, catalog no. GPWP04700) was laser cut using Epilog Fusion edge 24 laser cutter to
609 fit within the serpentine reaction chamber. The chambers were designed to be connected to the reaction
610 chamber through channels that are closed when under vacuum. Additionally, the chip has a channel and
611 waste port which allow for the integration of the EC sensor chip. The chip was sealed using a clear
612 delayed tack adhesive tape (3M 9795R) to prevent evaporation. Two high-power resistors were used as
613 heating elements for the sample preparation chamber and reaction chamber (Digikey 355018RJT) and
614 placed in a custom-printed backing to assure accurate and repeatable heading was provided. A full list of
615 parts along with cost analysis can be found in Supplementary Table S4. The voltages used for each
616 temperature are provided in **Supplementary Fig. S5** and were generated using an Agilent E3631A DC
617 power supply. A complete view of the microfluidic chip can be seen in **Fig. 1** and **Supplementary Fig.**
618 **S5**. A small DC pump (Takasago RP-Q series) connected to an Arduino Uno was used for the pumping.
619 The workflow for the multiplexed EC assay on the microfluidic chip is as follows: (1) The microfluidic
620 chip was sealed with clear delayed tack adhesive tape. (2) Saliva from patient samples (BioIVT) was
621 inactivated at 95°C for 5 min and mixed with 10% by volume of Proteinase K (NEB P8107S) that was
622 diluted 1:10 in nuclease free water. (3) 450 μL of the saliva mixture was added into the sample
623 preparation chamber and the chamber was heated to 55°C for 15 min, followed by 95°C for 5 min. (4)
624 The sample was pumped over the PES membrane within the reaction chamber at a speed of 50-
625 100 $\mu\text{L}/\text{min}$. (5) The reaction chamber was heated to 95°C for 3 min. (6) 25 μL of LAMP reaction (12.5 μL

626 of NEB 2X WarmStart Mastermix, 10 μ L of nuclease-free water, and 2.5 μ L 10x of LAMP primer mix)
627 was pumped into the reaction chamber and incubated at 65°C for 30 min. (7) The heat was decreased to
628 37°C and 22 μ L of the Cas mix (15 μ L nuclease-free water and 7 μ L of the CRISPR mix, which
629 contained 4 nM reporter, 100 nM Cas, 200 nM gRNA in 10X NEB 2.1 buffer) was pumped into the
630 reaction chamber and incubated for 30 min. (8) The LAMP/CRISPR reaction was pumped over the EC
631 sensor chip at 4 μ L/min for 5 min followed by 20 μ L of PBST at 15 μ L/min. (9) 20 μ L of saliva sample
632 spiked with NIBSC antibody calibrant mixed with anti-IgG detection antibody linked with biotin was
633 flowed through the EC sensor at 4 μ L/min for 5 min. (10) The EC sensor chip was washed with 20 μ L of
634 PBST at 15 μ L/min followed by addition of 20 μ L streptavidin-poly HRP at 6 μ L/min. (11) The EC
635 sensor chip was washed with 20 μ L of PBST at 15 μ L/min and 20 μ L of TMB at 8 μ L/min. (12) The EC
636 sensor chip was washed with 30 μ L of PBST at 15 μ L/min. (13) The EC sensor chip was read on a
637 potentiostat and the cyclic voltammogram was generated.

638

639 **Data analysis**

640 Fluorescence values are reported as absolute values for all experiments used for CRISPR-based
641 fluorescence assays. Absorbances for the ELISA assays are reported as background-subtracted values to
642 normalize for plate-to-plate variability. Peak oxidation current for EC CRISPR and serology assays was
643 calculated using Nova 1.11 software. All data were plotted and statistical tests were performed using
644 GraphPad Prism 9. Gold standards for ROC curve analysis: the individual samples for both serology and
645 viral RNA detection were validated using SARS-CoV-2 RT-qPCR. For molecular assays, SARS-CoV-2
646 positive saliva samples were RT-qPCR positive at the time of saliva collection. For serology assays,
647 SARS-CoV-2 positive plasma samples were RT-qPCR positive at the time of plasma or at an earlier date.
648 Receiver operating characteristic (ROC) curves were used to evaluate the performance of diagnostic
649 assays as a function of the discrimination threshold, plotted as sensitivity (%) versus 100 specificity (%).
650 The areas under the ROC curve (AUC) are a proxy of test performance, where 1 represents a perfect test
651 and 0.5 represents a random predictor. ROC curve analysis was done in GraphPad Prism 9 using a 95%

652 confidence interval and the Wilson/Brown method. Figures were created using Prism 9 and Adobe
653 Illustrator.

654

655 **Data availability**

656 All data needed to evaluate the conclusions of this work can be found in the paper and/or the
657 Supplementary Materials.

658

659 **Acknowledgements**

660 We would like to thank Tal Gilboa Hitron, Rose A. Lee and Nicole Weckman for helpful discussions and
661 advice. This work was supported by the Wyss Institute for Biologically Inspired Engineering at Harvard
662 University and the Paul G. Allen Frontiers Group. J.R. was funded through the UK Natural Environment
663 Research Council (NERC) GW4 FRESH CDT. H.D.P. was supported by the Harvard University Center
664 for AIDS Research (CFAR), an NIH-funded program (P30 AI060354), which is supported by the
665 following NIH co-funding and participating Institutes and Centers: NIAID, NCI, NICHD, NIDCR,
666 NHLBI, NIDA, NIMH, NIA, NIDDK, NINR, NIMHD, FIC, and OAR. M.Y. acknowledges Fonds de
667 recherche du Québec nature et technologie (FRQNT) postdoctoral fellowship #260284. The
668 MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and
669 Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness, and the Ragon
670 Institute of MGH, MIT and Harvard.

671

672 **Author contributions**

673 DN, JR, SS, PJ and HDP share the first author and contributed equally. DN, JR, SS, PJ, HDP, MY, ND,
674 HS conceived the study under the guidance of JAP, PE, JJC and DEI. Experiments were performed and
675 validated by DN, JR, SS, PJ, HDP. HDP and PJ formulated the idea, organized the experiments and
676 managed the project. MY, ND, DRW, GA, JZL, XGY contributed to the collection and characterization
677 of clinical serum and saliva samples. All authors contributed to manuscript preparation and editing.

678

679 **Competing interests**

680 HDP, PJ, JJC, DEI are inventors on patents describing the CRISPR EC sensing technology. PJ and DEI

681 are listed as inventors on patents describing the EC sensor platform. EC sensor platform technology has

682 been licensed to GBS Inc. for COVID-19 diagnostics and StataDX, Inc.; PJ and DEI hold equity in

683 StataDx and DEI is a board member. JJC and DRW are co-founders and directors of Sherlock

684 Biosciences. All other authors declare no competing interests.

685

686 **References**


- 687 1. Isho, B., *et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens
688 in COVID-19 patients. *Science Immunology* **5**, eabe5511 (2020).
- 689 2. Wolfel, R., *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* **581**,
690 465-469 (2020).
- 691 3. Pan, Y., Zhang, D.T., Yang, P., Poon, L.L.M. & Wang, Q.Y. Viral load of SARS-CoV-2 in
692 clinical samples. *Lancet Infectious Diseases* **20**, 411-412 (2020).
- 693 4. Zou, L.R., *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.
694 *New England Journal of Medicine* **382**, 1177-1179 (2020).
- 695 5. Gudbjartsson, D.F., *et al.* Humoral Immune Response to SARS-CoV-2 in Iceland. *New England*
696 *Journal of Medicine* **383**, 1724-1734 (2020).
- 697 6. Gaebler, C., *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644 (2021).
- 698 7. Van Elslande, J., *et al.* Antibody response against SARS-CoV-2 spike protein and nucleoprotein
699 evaluated by four automated immunoassays and three ELISAs. *Clinical Microbiology and*
700 *Infection* **26**, 1557.e1551-1557.e1557 (2020).
- 701 8. Dispinseri, S., *et al.* Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19
702 is persistent and critical for survival. *Nature Communications* **12**, 2670 (2021).
- 703 9. Nilsson, A.C., *et al.* Comparison of six commercially available SARS-CoV-2 antibody assays-
704 Choice of assay depends on intended use. *International Journal of Infectious Diseases* **103**, 381-
705 388 (2021).
- 706 10. Fenwick, C., *et al.* Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses
707 Impact the Estimates of Infections in Population-Based Seroprevalence Studies. *Journal of*
708 *Virology* **95**, e01828-01820 (2021).
- 709 11. Manisty, C., *et al.* Time series analysis and mechanistic modelling of heterogeneity and sero-
710 reversion in antibody responses to mild SARS-CoV-2 infection. *Ebiomedicine* **65**(2021).
- 711 12. Meyer, B., Drosten, C. & Muller, M.A. Serological assays for emerging coronaviruses:
712 Challenges and pitfalls. *Virus Research* **194**, 175-183 (2014).
- 713 13. Gilbert, P.B., *et al.* Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy
714 Trial. *medRxiv*, 2021.2008.2009.21261290 (2021).
- 715 14. Mak, G.C.K., *et al.* Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *Journal*
716 *of Clinical Virology* **129**(2020).
- 717 15. Chen, J.S., *et al.* CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase
718 activity. *Science* **360**, 436-439 (2018).
- 719 16. Gootenberg, J.S., *et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* **356**, 438-442
720 (2017).
- 721 17. Gootenberg, J.S., *et al.* Multiplexed and portable nucleic acid detection platform with Cas13,
722 Cas12a, and Csm6. *Science* **360**, 439-444 (2018).
- 723 18. Lee, R.A., *et al.* Ultrasensitive CRISPR-based diagnostic for field-applicable detection of
724 *Plasmodium* species in symptomatic and asymptomatic malaria. *Proceedings of the National*
725 *Academy of Sciences of the United States of America* **117**, 25722-25731 (2020).
- 726 19. Kaminski, M.M., *et al.* A CRISPR-based assay for the detection of opportunistic infections post-
727 transplantation and for the monitoring of transplant rejection. *Nature Biomedical Engineering* **4**,
728 601-609 (2020).

- 729 20. Gayet, R.V., *et al.* Creating CRISPR-responsive smart materials for diagnostics and
730 programmable cargo release. *Nature Protocols* **15**, 3030-3063 (2020).
- 731 21. English, M.A., *et al.* Programmable CRISPR-responsive smart materials. *Science* **365**, 780-785
732 (2019).
- 733 22. Zamani, M., *et al.* Electrochemical Strategy for Low-Cost Viral Detection. *Acs Central Science* **7**,
734 963-972 (2021).
- 735 23. Li, F., *et al.* An ultrasensitive CRISPR/Cas12a based electrochemical biosensor for *Listeria*
736 *monocytogenes* detection. *Biosensors & Bioelectronics* **179**(2021).
- 737 24. Hajian, R., *et al.* Detection of unamplified target genes via CRISPR–Cas9 immobilized on a
738 graphene field-effect transistor. *Nature Biomedical Engineering* **3**, 427 – 437 (2019).
- 739 25. Xu, W., Jin, T., Dai, Y.F. & Liu, C.C. Surpassing the detection limit and accuracy of the
740 electrochemical DNA sensor through the application of CRISPR Cas systems. *Biosensors &*
741 *Bioelectronics* **155**, 112100 (2020).
- 742 26. Bruch, R., *et al.* CRISPR/Cas13a-Powered Electrochemical Microfluidic Biosensor for Nucleic
743 Acid Amplification-Free miRNA Diagnostics. *Advanced Materials* **31**, 1905311 (2019).
- 744 27. de Puig, H., Bosch, I., Collins, J.J. & Gehrke, L. Point-of-Care Devices to Detect Zika and Other
745 Emerging Viruses. *Annual Review of Biomedical Engineering* **22**, 371-386 (2020).
- 746 28. Liu, R., *et al.* Analysis of adjunctive serological detection to nucleic acid test for severe acute
747 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. *International*
748 *Immunopharmacology* **86**(2020).
- 749 29. Torrente-Rodriguez, R.M., *et al.* SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed
750 Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring. *Matter*
751 **3**(2020).
- 752 30. Wyllie, A.L., *et al.* Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.
753 *New England Journal of Medicine* **383**, 1283-1286 (2020).
- 754 31. Ott, I.M., *et al.* Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive
755 collection devices. *medRxiv*, 2020.2008.2003.20165233 (2020).
- 756 32. Lalli, M.A., *et al.* Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by
757 Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification. *Clinical Chemistry*
758 **67**, 415-424 (2021).
- 759 33. Linnes, J.C., Rodriguez, N.M., Liu, L. & Klapperich, C.M. Polyethersulfone improves isothermal
760 nucleic acid amplification compared to current paper-based diagnostics. *Biomedical Microdevices*
761 **18**(2016).
- 762 34. Schlappi, T.S., McCalla, S.E., Schoepp, N.G. & Ismagilov, R.F. Flow-through Capture and in
763 Situ Amplification Can Enable Rapid Detection of a Few Single Molecules of Nucleic Acids
764 from Several Milliliters of Solution. *Analytical Chemistry* **88**, 7647-7653 (2016).
- 765 35. Rodriguez, N.M., *et al.* Paper-Based RNA Extraction, in Situ Isothermal Amplification, and
766 Lateral Flow Detection for Low-Cost, Rapid Diagnosis of Influenza A (H1N1) from Clinical
767 Specimens. *Analytical Chemistry* **87**, 7872-7879 (2015).
- 768 36. de Puig, H., *et al.* Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based
769 point-of-care diagnosis of SARS-CoV-2 and emerging variants. *Science Advances* **7**, eabh2944
770 (2021).

- 771 37. Rabe, B.A. & Cepko, C. SARS-CoV-2 detection using isothermal amplification and a rapid,
772 inexpensive protocol for sample inactivation and purification. *Proceedings of the National*
773 *Academy of Sciences of the United States of America* **117**, 24450-24458 (2020).
- 774 38. Lu, R.F., *et al.* Development of a Novel Reverse Transcription Loop-Mediated Isothermal
775 Amplification Method for Rapid Detection of SARS-CoV-2 (vol 18, pg 615, 2020). *Virologica*
776 *Sinica* **35**, 499-499 (2020).
- 777 39. Rohaim, M.A., *et al.* Artificial Intelligence-Assisted Loop Mediated Isothermal Amplification
778 (AI-LAMP) for Rapid Detection of SARS-CoV-2. *Viruses-Basel* **12**(2020).
- 779 40. Nawattanapaiboon, K., *et al.* Colorimetric reverse transcription loop-mediated isothermal
780 amplification (RT-LAMP) as a visual diagnostic platform for the detection of the emerging
781 coronavirus SARS-CoV-2. *Analyst* **146**, 471-477 (2021).
- 782 41. Yan, C., *et al.* Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse
783 transcription loop-mediated isothermal amplification assay. *Clinical Microbiology and Infection*
784 **26**, 773-779 (2020).
- 785 42. FDA. CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel (CDC) - Manufacturer
786 Instructions/Package Insert | FDA, (available at <https://www.fda.gov/media/134922/download>).
- 787 43. Zupancic, U., Jolly, P., Estrela, P., Moschou, D. & Ingber, D.E. Graphene Enabled Low-Noise
788 Surface Chemistry for Multiplexed Sepsis Biomarker Detection in Whole Blood. *Advanced*
789 *Functional Materials* **31**, 2010638 (2021).
- 790 44. Ter-Ovanesyan, D., *et al.* Ultrasensitive Measurement of Both SARS-CoV-2 RNA and
791 Antibodies from Saliva. *Analytical Chemistry* **93**, 5365-5370 (2021).
- 792 45. Satarker, S. & Nampoothiri, M. Structural Proteins in Severe Acute Respiratory Syndrome
793 Coronavirus-2. *Archives of Medical Research* **51**, 482-491 (2020).
- 794 46. Huang, Y., Yang, C., Xu, X.F., Xu, W. & Liu, S.W. Structural and functional properties of
795 SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta*
796 *Pharmacologica Sinica* **41**, 1141-1149 (2020).
- 797 47. Premkumar, L., *et al.* The receptor-binding domain of the viral spike protein is an
798 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science*
799 *Immunology* **5**, eabc8413 (2020).
- 800 48. Amanat, F., *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nature*
801 *Medicine* **26**, 1033-+ (2020).
- 802 49. Sterlin, D., *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-2.
803 *Science Translational Medicine* **13**(2021).
- 804 50. Zohar, T., *et al.* Compromised Humoral Functional Evolution Tracks with SARS-CoV-2
805 Mortality. *Cell* **183**, 1508-1519 (2020).
- 806 51. Yurkovetskiy, L., *et al.* Structural and Functional Analysis of the D614G SARS-CoV-2 Spike
807 Protein Variant. *Cell* **183**, 739-751 (2020).
- 808 52. Calistri, P., *et al.* Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by
809 longer persistence and higher viral RNA loads in nasopharyngeal swabs. *International Journal of*
810 *Infectious Diseases* **105**, 753-755 (2021).
- 811 53. Fajnzylber, J., *et al.* SARS-CoV-2 viral load is associated with increased disease severity and
812 mortality. *Nature Communications* **11**, 5493 (2020).


- 813 54. van Kampen, J.J.A., *et al.* Duration and key determinants of infectious virus shedding in
814 hospitalized patients with coronavirus disease-2019 (COVID-19). *Nature Communications* **12**,
815 267 (2021).
- 816 55. Golubchik, T., *et al.* Early analysis of a potential link between viral load and the N501Y mutation
817 in the SARS-COV-2 spike protein. *medRxiv*, 2021.2001.2012.20249080 (2021).
- 818 56. Qu, Y.M., Kang, E.M. & Cong, H.Y. Positive result of Sars-Cov-2 in sputum from a cured
819 patient with COVID-19. *Travel Medicine and Infectious Disease* **34**(2020).
- 820 57. Dörschug, A., *et al.* Comparative Assessment of Sera from Individuals after S-Genes RNA-Based
821 SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological
822 Assays. *Diagnostics (Basel)* **11**, 426 (2021).
- 823 58. Ndaye, A.N., Hoxha, A. & Madinga, J. Challenges in interpreting SARS-CoV-2 serological
824 results in African countries (vol 9, pg E588, 2021). *Lancet Global Health* **9**, E597-E597 (2021).
- 825 59. Schaffer DeRoo, S., Pudalov, N.J. & Fu, L.Y. Planning for a COVID-19 Vaccination Program.
826 *Jama-Journal of the American Medical Association* **323**, 2458-2459 (2020).
- 827 60. Timilsina, S.S., *et al.* Rapid antifouling nanocomposite coating enables highly sensitive
828 multiplexed electrochemical detection of myocardial infarction and concussion markers.
829 *medRxiv*, 2021.2006.2013.21258856 (2021).
- 830 61. Broughton, J.P., *et al.* CRISPR-Cas12-based detection of SARS-CoV-2. *Nature Biotechnology*
831 **38**, 870-874 (2020).
- 832 62. Rauch, J.N., *et al.* A Scalable, Easy-to-Deploy Protocol for Cas13-Based Detection of SARS-
833 CoV-2 Genetic Material. *Journal of Clinical Microbiology* **59**, e02402-02420 (2021).
- 834 63. Arizti-Sanz, J., *et al.* Streamlined inactivation, amplification, and Cas13-based detection of
835 SARS-CoV-2. *Nature Communications* **11**, 5921 (2020).
- 836 64. Lee, R.A., Herigon, J.C., Benedetti, A., Pollock, N.R. & Denkinger, C.M. Performance of Saliva,
837 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic
838 Review and Meta-analysis. *Journal of Clinical Microbiology* **59**, e02881-02820 (2021).
- 839 65. del Rio, J.S., Henry, O.Y.F., Jolly, P. & Ingber, D.E. An antifouling coating that enables affinity-
840 based electrochemical biosensing in complex biological fluids. *Nature Nanotechnology* **14**, 1143-
841 1149 (2019).
- 842 66. Jolly, P., Rainbow, J., Regoutz, A., Estrela, P. & Moschou, D. A PNA-based Lab-on-PCB
843 diagnostic platform for rapid and high sensitivity DNA quantification. *Biosensors &*
844 *Bioelectronics* **123**, 244-250 (2019).
- 845 67. Wang, L., Wang, X., Wu, Y., Guo, M., Gu, C., Dai, C., Kong, D., Wang, Y., Zhang, C., Qu, D.
846 and Fan, C. Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS
847 CoV-2 RNA in unamplified samples. *Nature Biomedical Engineering*, pp.1-10 (2022).
- 848
- 849

850 **Figures**



851
852 **Fig 1: Overview of multiplexed electrochemical sensor system.** (a) Overview of the microfluidic chip
853 designed for an LOC sample-to-answer saliva detection of SARS-CoV-2 RNA and antibodies. (1) The user
854 inputs saliva onto the antibody detection reservoir and a saliva and proteinase K mixture into the sample
855 preparation reservoir, where it incubates. (2) The saliva is pumped over the PES membrane inside the
856 reaction chamber for RNA capture and heated to denature potential reaction inhibitors. (3) The LAMP
857 solution is then pumped from the reservoir into the reaction chamber and incubated. (4) The CRISPR
858 mixture is pumped into the reaction chamber, incubated and then pumped over the EC sensor chip. (5)
859 The saliva for antibody detection is pumped over the EC sensor chip. (6) After the addition of
860 polystreptavidin-HRP and TMB, results from the EC sensor chip are read with a potentiostat. (b) An
861 exploded view of the multiplexed system, which includes a heater system, a sealed microfluidic chip, and
862 a multiplexed EC sensor chip. (c) Photograph of the microfluidic system with a quarter dollar for scale.

863
864



865

866 **Fig. 2. Schematic of the CRISPR electrochemical assays and assay performance using clinical**

867 **samples.** (a) Schematic illustrating the surface chemistry of the EC assay. Without viral RNA present, the

868 biotinylated ssDNA reporter probe is not cleaved; therefore, the poly-HRP streptavidin binds to the

869 PNA/biotin-DNA duplex when added to the EC sensor chip and consequently precipitates TMB resulting

870 in an increase in current. In contrast, the biotinylated reporter ssDNA is hydrolyzed in the presence of

871 viral target RNA, cleaving the biotin group. Consequently, poly-HRP streptavidin does not bind to the

872 surface of the chips, resulting in no TMB precipitation and no increase in current. (b) Cyclic


873 voltammogram showing the typical current peak signal achieved after incubation of samples from both

874 SARS-CoV-2 negative (orange) and positive (blue) clinical samples. (c) Clinical samples that contained

875 SARS-CoV-2 viral RNA (+, blue) had low signals in our device and were clearly distinguishable from the

876 *high signals obtained for samples that did not contain viral RNA (-, orange). Student's t-test p value*
877 *<0.001 (***). (d) Summary table listing the numerical values of the receiver operating characteristic*
878 *(ROC) curve analysis of the patient sample data collected for the SARS CoV-2 assay. The table shows a*
879 *summary of the results from 19 RT-qPCR confirmed positive and 10 negative human saliva samples.*
880 *AUC: area under the curve; 95% conf. Int.: 95% confidence interval; Sens: sensitivity; Spec.: specificity;*
881 *N pos.: number of RT-qPCR SARS-CoV-2 positive samples; N neg.: number of RT-qPCR SARS-CoV-2*
882 *negative clinical samples.*
883

884



885

886 **Fig. 3: Schematic and representative raw cyclic voltammetry data of the multiplexed serology assay. (a)**

887 *Schematic illustrating the multiplexed EC serological assay to assess host antibody responses on*

888 *electrodes functionalized with SARS-CoV-2 antigens. Host antibodies bind to the SARS-CoV-2 antigens*


889 *immobilized on the chips. Subsequently, biotinylated anti-human IgG secondary antibodies bind, followed*

890 *by poly HRP-streptavidin binding and TMB precipitation on the chips. (b-e) Typical cyclic*

891 *voltammograms for the four different electrodes that target host antibodies against (b) Spike 1 subunit*

892 (S1), (c) Spike 1-receptor binding domain (S1-RBD), (d) nucleocapsid (N), and (e) BSA negative control
893 (f) ROC curves generated from the patient sample data obtained for the IgG EC serology assay. (g) Table
894 listing the numerical values of the sensitivity and specificity results. AUC: area under the curve; 95%
895 conf. Int.: 95% confidence interval; Sens: sensitivity; Spec.: specificity; N pos.: number of gold standard
896 SARS-CoV-2 positive samples; N neg.: number of gold standard SARS-CoV-2 negative clinical samples.
897

898



899

900 **Fig. 4. Electrochemical platforms can be used for multiplexed sensing with simultaneous detection of**
901 **SARS-CoV-2 viral RNA and host antibodies against the virus.** (a) Schematic of the multiplexed chip
902 surface conjugated with SARS-CoV-2 antigens: Spike (S1), S1-Receptor binding domain (S1-RBD), and
903 Nucleocapsid (N); as well as peptide nucleic acid (PNA) for the detection of SARS-CoV-2 viral RNA on
904 the LOC microfluidic system. (b-e) Current (A) EC readout from the LOC microfluidic chip for clinical
905 samples containing different host antibody and viral RNA combinations: (b) Clinical samples negative for
906 both serology and viral RNA. (c) Clinical samples with negative host antibody levels and positive for viral
907 RNA. (d) Clinical samples that contain host antibodies against SARS-CoV-2 but are negative for viral
908 RNA. (e) Clinical samples with both positive host antibodies and viral RNA.

909